068760 — Celltrion Pharm Income Statement
0.000.00%
Last trade - 00:00
- KR₩4tn
- KR₩4tn
- KR₩389bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 173,513 | 233,568 | 398,738 | 386,040 | 388,794 |
Cost of Revenue | |||||
Gross Profit | 62,467 | 73,164 | 119,253 | 112,774 | 119,710 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 159,083 | 209,939 | 350,940 | 347,870 | 355,391 |
Operating Profit | 14,430 | 23,630 | 47,798 | 38,170 | 33,404 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 8,845 | 20,128 | 42,522 | 30,469 | 26,209 |
Provision for Income Taxes | |||||
Net Income After Taxes | 8,602 | 20,940 | 34,579 | 25,960 | 21,265 |
Net Income Before Extraordinary Items | |||||
Net Income | 8,602 | 20,940 | 34,579 | 25,960 | 21,265 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 8,602 | 20,940 | 34,579 | 25,960 | 21,265 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 225 | 504 | 835 | 625 | 556 |
Dividends per Share |